keyword
MENU ▼
Read by QxMD icon Read
search

Chemoradiation head and neck cancer

keyword
https://www.readbyqxmd.com/read/28323338/the-prognostic-value-of-extranodal-extension-in-human-papillomavirus-associated-oropharyngeal-squamous-cell-carcinoma
#1
Yi An, Henry S Park, Jacqueline R Kelly, John M Stahl, Wendell G Yarbrough, Barbara A Burtness, Joseph N Contessa, Roy H Decker, Matthew Koshy, Zain A Husain
BACKGROUND: Extranodal (or extracapsular) extension (ENE) is an adverse prognostic factor in patients with head and neck cancers who undergo primary surgery. However, the significance of ENE in human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC) is not well established, and single-institution studies have not established that ENE predicts inferior outcome. The authors investigated the prognostic value of ENE in HPV-positive patients who underwent primary surgery and whether adjuvant chemoradiation improved overall survival (OS) compared with radiation alone in ENE-positive patients...
March 21, 2017: Cancer
https://www.readbyqxmd.com/read/28317270/3q26-29-amplification-in-head-and-neck-squamous-cell-carcinoma-a-review-of-established-and-prospective-oncogenes
#2
REVIEW
Matthew A Davidson, Emma J Shanks
Head and neck cancer (HNSCC) is significantly underrepresented in worldwide cancer research, despite the fact that survival rates for the disease have remained static for over 50 years. Distant metastasis is often present at the time of diagnosis, and is the primary cause of death in cancer patients. In the absence of routine effective targeted therapies, the standard of care treatment remains chemoradiation in combination with (often disfiguring) surgery. A defining characteristic of HNSCC is the amplification of a region of chromosome 3 (3q26-29), which is consistently associated with poorer patient outcome...
March 19, 2017: FEBS Journal
https://www.readbyqxmd.com/read/28301066/effect-of-daily-fraction-size-on-laryngoesophageal-dysfunction-after-chemoradiation-for-squamous-cell-carcinomas-of-the-larynx-and-hypopharynx
#3
Allen M Chen, Sophia Hsu, Jessica Meshman, Robert Chin, Philip Beron, Elliot Abemayor, Maie St John
BACKGROUND: The purpose of this study was to determine the effect of fraction size on laryngoesophageal dysfunction among patients treated by chemoradiotherapy for laryngeal and hypopharyngeal cancer. METHODS: Forty patients underwent chemoradiotherapy for stage III/IV squamous cell carcinomas of the larynx and hypopharynx. Median radiation dose was 70 Gy (range, 69.3-70.4 Gy) with daily fractionation ranging from 2 Gy to 2.2 Gy. RESULTS: When comparing 2 Gy versus >2 Gy daily fractionation, there was no difference in 2-year overall survival (71% vs 72%; p = ...
March 16, 2017: Head & Neck
https://www.readbyqxmd.com/read/28274031/a-comparative-study-on-weekly-versus-three-weekly-cisplatinum-based-chemoradiation-in-locally-advanced-head-and-neck-cancers
#4
Tapan Kumar Sahoo, Dipti Rani Samanta, Surendra Nath Senapati, Karishma Parida
INTRODUCTION: Head and Neck Cancers constitute around 30% of cancers occurring in India and majority of cases present with locoregionally advanced disease. Cisplatin based concurrent chemoradiation is the most common modality of definitive treatment in these advanced cases. However, it is unclear regarding priority of weekly versus three weekly cisplatin based concurrent chemoradiation schedule in treatment of such advanced diseases. AIM: To evaluate the efficacy in terms of response, locoregional control, and disease status in both the arms, and to compare the acute and late toxicity in both arms...
January 2017: Journal of Clinical and Diagnostic Research: JCDR
https://www.readbyqxmd.com/read/28258889/geriatric-assessment-as-a-predictor-of-tolerance-quality-of-life-and-outcomes-in-older-patients-with-head-and-neck-cancers-and-lung-cancers-receiving-radiation-therapy
#5
Noam A VanderWalde, Allison M Deal, Elizabeth Comitz, Lori Stravers, Hyman Muss, Bryce B Reeve, Ethan Basch, Joel Tepper, Bhishamjit Chera
PURPOSE: To evaluate the association between functional status based on a geriatric assessment (GA) and outcomes of tolerance to treatment in patients with lung or head and neck cancer receiving radiation therapy (RT) or chemoradiation (CRT). METHODS AND MATERIALS: A prospective cohort study was conducted in patients aged ≥65 years with head and neck cancer or lung cancer undergoing curative intent RT or CRT. Pretreatment GA, health-related quality of life (HRQoL), and patient-reported outcomes (PRO) were obtained...
December 2, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28244415/a-randomized-phase-2-trial-of-prophylactic-manuka-honey-for-the-reduction-of-chemoradiation-therapy-induced-esophagitis-during-the-treatment-of-lung-cancer-results-of-nrg-oncology-rtog-1012
#6
Shannon E Fogh, Snehal Deshmukh, Lawrence B Berk, Amylou C Dueck, Kevin Roof, Sherif Yacoub, Thomas Gergel, Kevin Stephans, Andreas Rimner, Albert DeNittis, John Pablo, Justin Rineer, Terence M Williams, Deborah Bruner
PURPOSE: Randomized trials have shown that honey is effective for the prevention of radiation-induced mucositis in head and neck cancer patients. Because there is no efficacious preventative for radiation esophagitis in lung cancer patients, this trial compared liquid honey, honey lozenges, and standard supportive care for radiation esophagitis. METHODS: The patients were stratified by percentage of esophagus receiving specific radiation dose (V60 Gy esophagus <30% or ≥30%) and were then randomized between supportive care, 10 mL of liquid manuka honey 4 times a day, and 2 lozenges (10 mL of dehydrated manuka honey) 4 times a day during concurrent chemotherapy and radiation therapy...
March 15, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28197666/elevated-basal-antibody-dependent-cell-mediated-cytotoxicity-adcc-and-high-epidermal-growth-factor-receptor-egfr-expression-predict-favourable-outcome-in-patients-with-locally-advanced-head-and-neck-cancer-treated-with-cetuximab-and-radiotherapy
#7
Laura Lattanzio, Nerina Denaro, Daniela Vivenza, Chiara Varamo, Giuliana Strola, Mirella Fortunato, Emmanuel Chamorey, Alberto Comino, Martino Monteverde, Cristiana Lo Nigro, Gerard Milano, Marco Merlano
BACKGROUND: Antibody-dependent cell-mediated cytotoxicity (ADCC) may contribute to the antitumor activity of cetuximab. However, the extent of this contribution is unclear. In this study, we investigated the impact of baseline ADCC on the outcome of patients with locally advanced squamous cell carcinoma treated with cetuximab and radiotherapy. METHODS: We determined baseline ADCC in 28 patients treated with cetuximab and radiotherapy and in 15 patients treated with chemoradiation...
February 14, 2017: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/28179317/hypofractionated-palliative-radiotherapy-with-concurrent-radiosensitizing-chemotherapy-for-advanced-head-and-neck-cancer-using-the-quad-shot-regimen
#8
Mauricio E Gamez, Manuj Agarwal, Kenneth S Hu, John N Lukens, Louis B Harrison
AIM: To analyze the outcomes using the hypofractionated palliative radiotherapy regimen "QUAD-Shot" with concurrent radiosensitizing chemotherapy for advanced head and neck cancer. MATERIALS AND METHODS: We analyzed twenty-one patients with newly-diagnosed or recurrent head and neck cancer treated with palliative hypofractionated concurrent chemoradiation using the QUAD-Shot regimen. RESULTS: All patients received at least one cycle of RT, with sixteen patients (76%) completing all three cycles...
2017: Anticancer Research
https://www.readbyqxmd.com/read/28168166/evaluation-of-pet-mri-for-tumor-volume-delineation-for-head-and-neck-cancer
#9
Kyle Wang, Brandon T Mullins, Aaron D Falchook, Jun Lian, Kelei He, Dinggang Shen, Michael Dance, Weili Lin, Tiffany M Sills, Shiva K Das, Benjamin Y Huang, Bhishamjit S Chera
INTRODUCTION: Computed tomography (CT), combined positron emitted tomography and CT (PET/CT), and magnetic resonance imaging (MRI) are commonly used in head and neck radiation planning. Hybrid PET/MRI has garnered attention for potential added value in cancer staging and treatment planning. Herein, we compare PET/MRI vs. planning CT for head and neck cancer gross tumor volume (GTV) delineation. MATERIAL AND METHODS: We prospectively enrolled patients with head and neck cancer treated with definitive chemoradiation to 60-70 Gy using IMRT...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28156440/patient-reported-outcomes-pros-in-patients-with-human-papilloma-virus-hpv-positive-versus-negative-head-and-neck-cancer-hnc
#10
Areej El-Jawahri, Karen Quinn, Lisa Arcikowski, Gina Chan, Elene Viscosi, Carol Doherty, John Ross Clark, Lori J Wirth, Jennifer S Temel
87 Background: HNC caused by HPV has become an epidemic. Treatment for HNC results in a tremendous symptom burden. The impact of HPV-status on quality of life (QOL) and how this effects illness perception and mood has not been described. We sought to explore differences in PROs in patients with HPV + vs. - HNC. METHODS: This is a secondary analysis of data from a prospective, longitudinal intervention study of 60 patients with newly diagnosed HNC undergoing concurrent chemoradiation. 30 control patients received standard care followed by 30 intervention patients who received an educational intervention...
October 9, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28126298/hyperbaric-oxygen-as-radiation-sensitizer-for-locally-advanced-squamous-cell-carcinoma-of-the-oropharynx-a-phase-1-dose-escalation-study
#11
Alan C Hartford, Thomas H Davis, Jay C Buckey, Robert L Foote, Mark S Sinesi, Benjamin B Williams, Anna K Fariss, Philip E Schaner, Paul L Claus, Scott H Okuno, James R Hussey, Richard E Clarke
PURPOSE: To explore, in a dose-escalation study, the feasibility of hyperbaric oxygen (HBO) treatments immediately before intensity modulated radiation therapy in conjunction with cisplatinum chemotherapy for squamous cell carcinoma of the head and neck (SCCHN). METHODS AND MATERIALS: Eligible patients presented with SCCHN (stage III-IV [M0]), life expectancy >6 months, and Karnofsky performance status ≥70. Enrollees received intensity modulated radiation therapy, 70 Gy in 35 fractions over 7 weeks with weekly cisplatinum...
March 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28111634/temporal-feature-extraction-from-dce-mri-to-identify-poorly-perfused-subvolumes-of-tumors-related-to-outcomes-of-radiation-therapy-in-head-and-neck-cancer
#12
Daekeun You, Madhava Aryal, Stuart E Samuels, Avraham Eisbruch, Yue Cao
This study aimed to develop an automated model to extract temporal features from DCE-MRI in head-and-neck (HN) cancers to localize significant tumor subvolumes having low blood volume (LBV) for predicting local and regional failure after chemoradiation therapy. Temporal features were extracted from time-intensity curves to build classification model for differentiating voxels with LBV from those with high BV. Support vector machine (SVM) classification was trained on the extracted features for voxel classification...
December 2016: Tomography: a Journal for Imaging Research
https://www.readbyqxmd.com/read/28062933/single-cycle-induction-chemotherapy-for-resectable-advanced-hypopharyngeal-cancer
#13
Torahiko Nakashima, Ryuji Yasumatsu, Kaori Asai, Hideoki Uryu, Ryunosuke Kogo, Takashi Nakagawa
BACKGROUND: The role of induction chemotherapy (IC) in the treatment of resectable advanced head and neck squamous cell carcinoma has not been elucidated, and the most effective IC regimen for chemoselection is still unknown. At our institute we have not used the triple combination of docetaxel, cisplatin, fluorouracil (TPF) for chemoselection, but rather the double combination of docetaxel + cisplatin (TP). The aim of this study is to report the outcome of patients with advanced hypopharyngeal cancer treated by single cycle of IC with TP followed by chemoradiation (CRT) or surgery...
January 6, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28054529/a-retrospective-analysis-of-patients-with-head-and-neck-cancer-treated-with-radiation-hyperthermia-and-cetuximab-a-brief-report-of-outcome
#14
Nagraj G Huilgol
PURPOSE: Advanced head and neck cancer continues to have a dismal outcome. Chemoradiation remains the current standard of care. Chemoradiation has not achieved the desired increase in survival in locally advanced head and neck cancer. This is a retrospective analysis of six patients treated with hyperthermia, radiation therapy, and cetuximab. We wished to determine if this combination treatment would further improve the outcome. MATERIALS AND METHODS: Six patients with squamous cell cancer of the head and neck region were treated with hyperthermia, cetuximab, and radiation therapy...
July 2016: Journal of Cancer Research and Therapeutics
https://www.readbyqxmd.com/read/28034498/genomic-sequencing-and-precision-medicine-in-head-and-neck-cancers
#15
REVIEW
R C Hoesli, M L Ludwig, N L Michmerhuizen, A J Rosko, M E Spector, J C Brenner, A C Birkeland
Head and neck squamous cell carcinoma (HNSCC) remains a common and deadly disease. Historically, surgical and chemoradiation treatments have been met with modest success, and understanding of genetic drivers of HNSCC has been limited. With recent next generation sequencing studies focused on HNSCC, we are beginning to understand the genetic landscape of HNSCCs and are starting to identify and advance targeted options for patients. In this review, we describe current knowledge and recent advances in sequencing studies of HNSCC, discuss current limitations and future directions for further genomic analysis, and highlight the translational advances being undertaken to treat this important disease...
December 15, 2016: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28001302/impact-of-concomitant-chemoradiation-on-survival-for-patients-with-t1-2n1-head-and-neck-cancer
#16
Zachary S Zumsteg, Sungjin Kim, John M David, Emi J Yoshida, Mourad Tighiouart, Stephen L Shiao, Kevin Scher, Alain Mita, Eric J Sherman, Nancy Y Lee, Allen S Ho
BACKGROUND: Single-modality radiotherapy is considered a standard-of-care option for certain stage III, T1-2N1 head and neck squamous cell carcinomas (HNSCCs). The role of concomitant chemoradiation is not well established because there have been no studies comparing chemoradiation with radiation alone in this population. METHODS: This study analyzed patients in the National Cancer Data Base with cT1-2N1M0 invasive squamous cell carcinomas of the oropharynx, larynx, and hypopharynx who were diagnosed between 2004 and 2012 and were undergoing definitive radiation...
December 21, 2016: Cancer
https://www.readbyqxmd.com/read/27980104/the-fa-brca-pathway-identified-as-the-major-predictor-of-cisplatin-response-in-head-and-neck-cancer-by-functional-genomics
#17
Sanne R Martens-de Kemp, Arjen Brink, Ida H van der Meulen, Renee X De Menezes, Dennis E Te Beest, C Rene Leemans, Victor W van Beusechem, Boudewijn J M Braakhuis, Ruud H Brakenhoff
Patients with advanced stage head and neck squamous cell carcinoma (HNSCC) are often treated with cisplatin-containing chemoradiation protocols. Although cisplatin is an effective radiation sensitizer, it causes severe toxicity and not all patients benefit from the combination treatment. HNSCCs expectantly not responding to cisplatin may better be treated with surgery and postoperative radiation or cetuximab and radiation, but biomarkers to personalize chemoradiotherapy, are not available. We performed an unbiased genome-wide functional genetic screen in vitro to identify genes that influence the response to cisplatin in HNSCC cells...
December 15, 2016: Molecular Cancer Therapeutics
https://www.readbyqxmd.com/read/27965848/a-feasibility-study-incorporating-a-pilot-randomised-controlled-trial-of-oral-feeding-plus-pre-treatment-gastrostomy-tube-versus-oral-feeding-plus-as-needed-nasogastric-tube-feeding-in-patients-undergoing-chemoradiation-for-head-and-neck-cancer-tube-trial-study
#18
Vinidh Paleri, Joshua Wood, Joanne Patterson, Deborah D Stocken, Mike Cole, Luke Vale, Jeremy Franks, Teresa Guerrero-Urbano, Rachael Donnelly, Stewart Barclay, Tim Rapley, Nikki Rousseau
BACKGROUND: There are 7000 new cases of head and neck squamous cell cancers (HNSCC) treated by the NHS each year. Stage III and IV HNSCC can be treated non-surgically by radio therapy (RT) or chemoradiation therapy (CRT). CRT can affect eating and drinking through a range of side effects with 90 % of patients undergoing this treatment requiring nutritional support via gastrostomy (G) or nasogastric (NG) tube feeding. Long-term dysphagia following CRT is a primary concern for patients...
2016: Pilot and Feasibility Studies
https://www.readbyqxmd.com/read/27881143/weekly-versus-every-three-weeks-platinum-based-chemoradiation-regimens-for-head-and-neck-cancer
#19
James M Melotek, Benjamin T Cooper, Matthew Koshy, Joshua S Silverman, Michael T Spiotto
BACKGROUND: The majority of chemoradiation (CRT) trials for locally advanced head and neck squamous cell carcinoma (HNSCC) have relied on platinum-based chemotherapy regimens administered every-3-weeks. However, given the increased utilization of weekly platinum regimens, it remains unclear how different chemotherapy schedules compare regarding efficacy and toxicity. METHODS: We retrospectively identified 212 patients with HNSCC who were treated at a single academic medical center with concurrent platinum-based CRT given weekly (N = 68) or every-three-weeks (N = 144)...
November 24, 2016: Journal of Otolaryngology—Head & Neck Surgery
https://www.readbyqxmd.com/read/27869097/the-impact-of-radiation-treatment-time-on-survival-in-patients-with-head-and-neck-cancer
#20
Talha Shaikh, Elizabeth A Handorf, Colin T Murphy, Ranee Mehra, John A Ridge, Thomas J Galloway
PURPOSE: To assess the impact of radiation treatment time (RTT) in head and neck cancers on overall survival (OS) in the era of chemoradiation. METHODS AND MATERIALS: Patients with diagnoses of tongue, hypopharynx, larynx, oropharynx, or tonsil cancer were identified by use of the National Cancer Database. RTT was defined as date of first radiation treatment to date of last radiation treatment. In the definitive setting, prolonged RTT was defined as >56 days, accelerated RTT was defined as <47 days, and standard RTT was defined as 47 to 56 days...
December 1, 2016: International Journal of Radiation Oncology, Biology, Physics
keyword
keyword
36807
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"